Ascentage Pharma Announces 2022 Interim Results

SUZHOU, China and ROCKVILLE, Md. , Aug. 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis

Related Keywords

China , Australia , United States , Rockville , Pennsylvania , Hong Kong , Hainan , Philadelphia , Suzhou , Jiangsu , Canada , Chinese , American , Innovent Biologics , Ascentage Pharma , Dajun Yang , Tanner Pharma , Prnewswire Ascentage Pharma , Major National , American Society Of Clinical Oncology , European Hematology Association , European Molecular Biology Organization , Md Anderson Cancer Center , Pfizer , China National Medical Products Administration , Astrazeneca , National Major New Drug Discovery , Dana Farber Cancer Institute , Chinese Society Of Clinical Oncology , Cancer Association , National Major New Drug Development , Drug Administration , Health Canada , Manufacturing Program , Patient Program , Chinese Society , Clinical Oncology , China Anti Cancer Association , Holistic Integrative Management , Named Patient Program , Drug Evaluation , Priority Review , New Drug Application , Annual Meeting , Rare Pediatric Disease , Hematology Association , Main Board , Stock Exchange , Hong Kong Limited , Breakthrough Therapy Designation , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Pediatric Disease , Major National Rd Projects , Major New Drug Discovery , Drug Incubator , Drug Programs , Cancer Center , Mayo Clinic , Ascentage , Dharma , Nnounces , 022 , Interim , Results ,